Structure Therapeutics (GPCR) shares almost doubled in recent Monday trading after the company reported that its obesity drug candidate aleniglipron achieved statistical significance in the Phase 2b study's primary and key secondary endpoints.

Aleniglipron delivered a clinically meaningful placebo-adjusted mean weight loss of 11.3% at 36 weeks with a 120-milligram dose, while lower doses of 45 mg and 90 mg also produced weight reductions, the company said.

The drug additionally showed improvements in systolic blood pressure and a tolerability profile consistent with the GLP-1 receptor agonist class, the company said.

Structure Therapeutics plans to request a Type B End-of-Phase 2 meeting with the US Food and Drug Administration in H1 2026 to finalize the design of its Phase 3 program, which it aims to initiate by mid-2026.

"The topline results presented today show that aleniglipron is differentiated and delivered clinically meaningful, competitive and dose-dependent weight loss with a safety profile appropriate for chronic use in a disease that impacts millions of people," Structure Therapeutics Chief Executive Officer Raymond Stevens said in a statement.

Price: 68.65, Change: +34.09, Percent Change: +98.64